JP7499228B2 - 神経成長因子に対するモノクローナル抗体、並びにそれをコードする遺伝子及びその使用 - Google Patents
神経成長因子に対するモノクローナル抗体、並びにそれをコードする遺伝子及びその使用 Download PDFInfo
- Publication number
- JP7499228B2 JP7499228B2 JP2021506024A JP2021506024A JP7499228B2 JP 7499228 B2 JP7499228 B2 JP 7499228B2 JP 2021506024 A JP2021506024 A JP 2021506024A JP 2021506024 A JP2021506024 A JP 2021506024A JP 7499228 B2 JP7499228 B2 JP 7499228B2
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- antigen
- antibody
- binding fragment
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title claims description 82
- 102000015336 Nerve Growth Factor Human genes 0.000 title claims description 81
- 229940053128 nerve growth factor Drugs 0.000 title claims description 78
- 108090000623 proteins and genes Proteins 0.000 title description 20
- 239000000427 antigen Substances 0.000 claims description 46
- 108091007433 antigens Proteins 0.000 claims description 46
- 102000036639 antigens Human genes 0.000 claims description 46
- 230000027455 binding Effects 0.000 claims description 45
- 238000009739 binding Methods 0.000 claims description 41
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 29
- 208000002193 Pain Diseases 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 7
- 208000000094 Chronic Pain Diseases 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 206010065390 Inflammatory pain Diseases 0.000 claims description 5
- 229940127121 immunoconjugate Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 35
- 230000000694 effects Effects 0.000 description 18
- 229950008160 tanezumab Drugs 0.000 description 18
- 230000004663 cell proliferation Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000000629 knee joint Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 238000010609 cell counting kit-8 assay Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000012160 loading buffer Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 229940122467 Nerve growth factor antagonist Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000015533 trkA Receptor Human genes 0.000 description 1
- 108010064884 trkA Receptor Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/48—Nerve growth factor [NGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Description
ここでその相補性決定領域HCDR1のアミノ酸配列はSEQ ID NO:5に記述され;
その相補性決定領域HCDR2のアミノ酸配列はSEQ ID NO:6に記述され;
その相補性決定領域HCDR3のアミノ酸配列はSEQ ID NO:7に記述され;
その相補性決定領域LCDR1のアミノ酸配列はSEQ ID NO:8に記述され;
その相補性決定領域LCDR2のアミノ酸配列はSEQ ID NO:9に記述され;及びその相補性決定領域LCDR3のアミノ酸配列はSEQ ID NO:10に記述される。
並びに/又は
神経障害性疼痛、慢性疼痛、及び炎症性疼痛を治療又は予防するために用いることができ。
Claims (19)
- 神経成長因子(NGF)に対するモノクローナル抗体又はその抗原結合断片であって、前記モノクローナル抗体が重鎖定常領域及び重鎖可変領域を含む重鎖、並びに、軽鎖定常領域及び軽鎖可変領域を含む軽鎖を含み、ここで重鎖可変領域が3つの相補性決定領域HCDR1、HCDR2及びHCDR3を含むと共に、軽鎖可変領域が3つの相補性決定領域LCDR1、LCDR2及びLCDR3を含み;前記HCDR1のアミノ酸配列が配列番号5に記載の配列であり;前記HCDR2のアミノ酸配列が配列番号6に記載の配列であり;前記HCDR3のアミノ酸配列が配列番号7に記載の配列であり;前記LCDR1のアミノ酸配列が配列番号8に記載の配列であり;前記LCDR2のアミノ酸配列が配列番号9に記載の配列であり;前記LCDR3のアミノ酸配列が配列番号10に記載の配列である;モノクローナル抗体又はその抗原結合断片。
- 前記重鎖可変領域のアミノ酸配列が、配列番号2に記載の配列であり;前記軽鎖可変領域のアミノ酸配列が配列番号4に記載の配列である、請求項1に記載のモノクローナル抗体又はその抗原結合断片。
- Fab、Fab’、F(ab’)2 、Fv、一本鎖抗体、ヒト化抗体、キメラ抗体、及び二重特異性抗体より選択される、請求項1又は2に記載のモノクローナル抗体又はその抗原結合断片。
- NGFタンパク質と結合し100nM未満のEC50を有する、請求項1~3の何れか一項に記載のモノクローナル抗体又はその抗原結合断片。
- マウス以外の種に由来する非CDR領域を含む、請求項1~4の何れか一項に記載のモノクローナル抗体又はその抗原結合断片。
- 請求項1~5の何れか一項に記載の神経成長因子に対するモノクローナル抗体又はその抗原結合断片の重鎖可変領域をコードするヌクレオチド配列及び軽鎖可変領域をコードするヌクレオチド配列を含む核酸分子。
- 前記重鎖可変領域をコードするヌクレオチド配列が配列番号1に記載の配列であり;前記軽鎖可変領域をコードするヌクレオチド配列が配列番号3に記載の配列である、請求項6に記載の核酸分子。
- 請求項6又は7に記載の核酸分子を含むベクター。
- 請求項6又は7に記載の核酸分子又は請求項8に記載のベクターを含む宿主細胞。
- 請求項1~5の何れか一項に記載のモノクローナル抗体又はその抗原結合断片、及びそれに結合した複合体部分を含み、前記複合体部分が検出可能な標識であるモノクローナル抗体複合体。
- 前記複合体部分がラジオアイソトープ、発光基質、有色基質、又は酵素である、請求項10に記載のモノクローナル抗体複合体。
- 請求項1~5の何れか一項に記載のモノクローナル抗体若しくはその抗原結合断片及び/又は請求項10若しくは11に記載のモノクローナル抗体複合体を含むキット。
- 請求項1~5の何れか一項に記載のモノクローナル抗体又はその抗原結合断片を特異的に認識する第二の抗体をさらに含む請求項12に記載のキット。
- 神経成長因子の存在及び/又はレベルを検出するための医薬の調製における請求項1~5の何れか一項に記載のモノクローナル抗体若しくはその抗原結合断片及び/又は請求項10若しくは11に記載のモノクローナル抗体複合体の使用。
- 神経成長因子に特異的に結合する薬物;神経成長因子依存性TF-1細胞の増殖を阻害する医薬の調製における請求項1~5の何れか一項に記載のモノクローナル抗体若しくはその抗原結合断片及び/又は請求項10若しくは11に記載のモノクローナル抗体複合体の使用。
- 神経障害性疼痛、慢性疼痛、及び炎症性疼痛の少なくとも一つを治療又は予防するための医薬の調製における、請求項1~5の何れか一項に記載のモノクローナル抗体若しくはその抗原結合断片及び/又は請求項10若しくは11に記載のモノクローナル抗体複合体の使用。
- 有効成分として請求項1~5の何れか一項に記載のモノクローナル抗体若しくはその抗原結合断片及び/又は請求項10若しくは11に記載のモノクローナル抗体複合体、及び医薬的に許容可能な担体又は賦形剤を含む医薬組成物。
- 前記モノクローナル抗体若しくはその抗原結合断片が神経成長因子に特異的に結合し、TF-1細胞の神経成長因子依存性の増殖を阻害する、請求項17に記載の医薬組成物。
- 神経障害性疼痛、慢性疼痛、及び炎症性疼痛の少なくとも一つを治療又は予防するための、請求項17又は18に記載の医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810344670.3A CN108623687A (zh) | 2018-04-17 | 2018-04-17 | 神经生长因子的单克隆抗体及其编码基因和应用 |
CN201810344670.3 | 2018-04-17 | ||
CN201811320006.1 | 2018-11-07 | ||
CN201811320006.1A CN109553683A (zh) | 2018-04-17 | 2018-11-07 | 神经生长因子的单克隆抗体及其编码基因和应用 |
PCT/CN2019/082107 WO2019201133A1 (zh) | 2018-04-17 | 2019-04-10 | 神经生长因子的单克隆抗体及其编码基因和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021521881A JP2021521881A (ja) | 2021-08-30 |
JP7499228B2 true JP7499228B2 (ja) | 2024-06-13 |
Family
ID=63705267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021506024A Active JP7499228B2 (ja) | 2018-04-17 | 2019-04-10 | 神経成長因子に対するモノクローナル抗体、並びにそれをコードする遺伝子及びその使用 |
Country Status (15)
Country | Link |
---|---|
US (2) | US11680095B2 (ja) |
EP (1) | EP3783021A4 (ja) |
JP (1) | JP7499228B2 (ja) |
KR (1) | KR20200143471A (ja) |
CN (3) | CN108623687A (ja) |
AU (1) | AU2019254934A1 (ja) |
BR (1) | BR112020021256A2 (ja) |
CA (1) | CA3097414A1 (ja) |
EA (1) | EA202092491A1 (ja) |
IL (1) | IL277982A (ja) |
MX (1) | MX2020010863A (ja) |
PH (1) | PH12020551678A1 (ja) |
SG (1) | SG11202010150PA (ja) |
WO (1) | WO2019201133A1 (ja) |
ZA (1) | ZA202006317B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108623687A (zh) | 2018-04-17 | 2018-10-09 | 中山康方生物医药有限公司 | 神经生长因子的单克隆抗体及其编码基因和应用 |
CN110684106B (zh) * | 2019-09-30 | 2021-02-02 | 达石药业(广东)有限公司 | 一种靶向神经生长因子的单克隆抗体及其应用 |
CN117003868B (zh) * | 2020-04-17 | 2024-04-16 | 珠海泰诺麦博制药股份有限公司 | 抗人神经生长因子的抗体 |
CN113527483B (zh) * | 2020-04-17 | 2023-09-22 | 珠海泰诺麦博制药股份有限公司 | 抗人神经生长因子的抗体 |
CN113993900B (zh) * | 2020-05-27 | 2023-08-04 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别神经生长因子的抗体及其用途 |
CN114470189B (zh) * | 2020-11-12 | 2024-01-16 | 达石药业(广东)有限公司 | Ngf抗体在cipn性疼痛中的应用 |
CN113444176B (zh) * | 2021-06-02 | 2022-10-14 | 武汉人福创新药物研发中心有限公司 | Ngf的抗体及其应用 |
CN114729330A (zh) | 2021-07-30 | 2022-07-08 | 成都优洛生物科技有限公司 | 一种重组cho细胞、其构建方法、利用其的检测***和方法 |
CN116836276B (zh) * | 2023-07-28 | 2023-12-08 | 艾可泰科(浙江)控股有限公司 | 一种用于修复膝关节损伤的干细胞制剂及其制备工艺 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006525955A (ja) | 2002-12-24 | 2006-11-16 | ライナット ニューロサイエンス コーポレイション | 抗ngf抗体およびそれらを使用する方法 |
JP2012525838A (ja) | 2009-05-04 | 2012-10-25 | アボット・リサーチ・ベー・フェー | 生体内における安定性を向上させた神経成長因子(ngf)に対する抗体 |
JP2014507116A (ja) | 2010-12-01 | 2014-03-27 | アルダーバイオ ホールディングス エルエルシー | 抗ngf組成物およびその使用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
AU2011201157C1 (en) * | 2002-12-24 | 2017-09-07 | Rinat Neuroscience Corp. | Anti-NGF antibodies and methods using same |
EA030259B8 (ru) * | 2003-07-15 | 2018-09-28 | Амджен Инк. | Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf |
CA2562024C (en) | 2004-04-07 | 2014-05-27 | Rinat Neuroscience Corp. | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
AU2012201465A1 (en) * | 2005-06-07 | 2012-04-05 | Abbott Research B.V | Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect |
AU2008287037B2 (en) | 2007-08-10 | 2013-10-10 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
CN104910274B (zh) * | 2015-02-12 | 2018-05-04 | 北京华安科创生物技术有限公司 | 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株 |
CN108623687A (zh) * | 2018-04-17 | 2018-10-09 | 中山康方生物医药有限公司 | 神经生长因子的单克隆抗体及其编码基因和应用 |
-
2018
- 2018-04-17 CN CN201810344670.3A patent/CN108623687A/zh active Pending
- 2018-11-07 CN CN201811320006.1A patent/CN109553683A/zh active Pending
-
2019
- 2019-04-10 US US17/048,442 patent/US11680095B2/en active Active
- 2019-04-10 SG SG11202010150PA patent/SG11202010150PA/en unknown
- 2019-04-10 CA CA3097414A patent/CA3097414A1/en active Pending
- 2019-04-10 AU AU2019254934A patent/AU2019254934A1/en active Pending
- 2019-04-10 CN CN201980026536.1A patent/CN112166121B/zh active Active
- 2019-04-10 MX MX2020010863A patent/MX2020010863A/es unknown
- 2019-04-10 JP JP2021506024A patent/JP7499228B2/ja active Active
- 2019-04-10 EP EP19788116.2A patent/EP3783021A4/en active Pending
- 2019-04-10 EA EA202092491A patent/EA202092491A1/ru unknown
- 2019-04-10 BR BR112020021256-3A patent/BR112020021256A2/pt unknown
- 2019-04-10 KR KR1020207032938A patent/KR20200143471A/ko active Search and Examination
- 2019-04-10 WO PCT/CN2019/082107 patent/WO2019201133A1/zh unknown
-
2020
- 2020-10-12 IL IL277982A patent/IL277982A/en unknown
- 2020-10-12 ZA ZA2020/06317A patent/ZA202006317B/en unknown
- 2020-10-12 PH PH12020551678A patent/PH12020551678A1/en unknown
-
2023
- 2023-05-22 US US18/321,711 patent/US20240025983A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006525955A (ja) | 2002-12-24 | 2006-11-16 | ライナット ニューロサイエンス コーポレイション | 抗ngf抗体およびそれらを使用する方法 |
JP2012525838A (ja) | 2009-05-04 | 2012-10-25 | アボット・リサーチ・ベー・フェー | 生体内における安定性を向上させた神経成長因子(ngf)に対する抗体 |
JP2014507116A (ja) | 2010-12-01 | 2014-03-27 | アルダーバイオ ホールディングス エルエルシー | 抗ngf組成物およびその使用 |
Also Published As
Publication number | Publication date |
---|---|
EA202092491A1 (ru) | 2021-02-09 |
US20210155683A1 (en) | 2021-05-27 |
JP2021521881A (ja) | 2021-08-30 |
US11680095B2 (en) | 2023-06-20 |
CN112166121A (zh) | 2021-01-01 |
PH12020551678A1 (en) | 2021-06-07 |
IL277982A (en) | 2020-11-30 |
EP3783021A1 (en) | 2021-02-24 |
BR112020021256A2 (pt) | 2021-02-02 |
CN108623687A (zh) | 2018-10-09 |
MX2020010863A (es) | 2021-01-29 |
SG11202010150PA (en) | 2020-11-27 |
AU2019254934A1 (en) | 2020-11-19 |
CN109553683A (zh) | 2019-04-02 |
CA3097414A1 (en) | 2019-10-24 |
EP3783021A4 (en) | 2022-03-02 |
ZA202006317B (en) | 2024-01-31 |
KR20200143471A (ko) | 2020-12-23 |
US20240025983A1 (en) | 2024-01-25 |
CN112166121B (zh) | 2022-11-22 |
WO2019201133A1 (zh) | 2019-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7499228B2 (ja) | 神経成長因子に対するモノクローナル抗体、並びにそれをコードする遺伝子及びその使用 | |
WO2017071625A1 (zh) | 一种抗pd-1单克隆抗体、其药物组合物及其用途 | |
US11402383B2 (en) | Nucleic acid encoding PCSK9 antibody | |
KR20200119846A (ko) | 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도 | |
CA2877669A1 (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
US20230109780A1 (en) | Anti-ngf antibody and antigen-binding fragment thereof, preparation method, and application thereof | |
CN111196849B (zh) | 抗硬骨素抗体、其抗原结合片段及其医药用途 | |
EP4155322A1 (en) | Anti-trka antibody or antigen-binding fragment thereof, preparation method therefor, and application thereof | |
WO2014016702A2 (en) | Humanized forms of monoclonal antibodies to human gnrh receptor | |
TWI685504B (zh) | 抗gitr抗體、其抗原結合片段及其醫藥用途 | |
KR20230004659A (ko) | 항-인간 신경 성장 인자 항체 | |
EA044828B1 (ru) | Моноклональное антитело против фактора роста нервов, кодирующий его ген и его применение | |
EA046350B1 (ru) | Анти-интерлейкин-17а антитело, фармацевтическая композиция и их применение | |
CN114269788A (zh) | 一种能够与人4-1bb结合的分子及其应用 | |
TW202144425A (zh) | 特異性抗原結合分子,其製備方法及醫藥用途 | |
JP2024105575A (ja) | 特定の腸内細菌の抗体媒介中和による免疫疾患の治療 | |
CN117903313A (zh) | 一种抗iars抗体及其应用 | |
CN116133684A (zh) | 抗人nr1抗体衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201026 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220331 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230914 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240213 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240521 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240603 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7499228 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |